Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
But financing sizes have grown by a similar amount on both sides of the Atlantic.